HRD-Portal

The QuIP HRD-Portal was established to provide pathologists, consultants from various medical fields, and oncologists with guidance at the intersection of biomarker testing and therapy options. Serving as an interdisciplinary resource, the portal supports diagnostics, molecular pathology, and therapy planning, drawing on both the latest scientific research and current medical guidelines.

QuIP is committed to supporting pathologists across Germany and Europe in enhancing the accuracy of their diagnostic results and providing assistance in all key professional and organizational aspects related to quality assurance.

The portal offers foundational knowledge on DNA repair defects, and detailing both the testing of underlying causes (such as mutations in the HRR genes such as BRCA1/2) and the effects of these defects (e.g. GI score).

Additionally, the algorithm provides comprehensive information on tests, potential outcomes, and treatment options for various cancers, including pancreatic, ovarian, breast, and prostate. This content is informed by current EMA-based medical guidelines and the latest scientific research.

The research literature used by the portal's content authors is cited in a dedicated "References" tab on each relevant algorithm page. These references reflect the latest advancements in the field as determined by scientific experts and are regularly reviewed and updated by the team as needed.

Due to data protection regulations in Germany, QuIP is unable to publicly share the full portal or provide an open link to the website. While the introductory section is visible on the portal's homepage, the remaining content is restricted to medical professionals.

Registered QuIP users will automatically see a link to the HRD-Portal after logging into the QuIP homepage. Physicians with DocCheck access can also enter the HRD-Portal. Other interested parties who do not have a QuIP account or DocCheck access can request entry by emailing QuIP. An access code will be provided after verifying the requestor's eligibility.

QuIP is supported by AstraZeneca, GlaxoSmithKline, Janssen-Cilag, MSD Sharp & Dohme and Pfizer.

Status: June 2024